Navigation Links
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Date:3/5/2008

eveloping, producing and selling Zevalin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm

Medical Information Contact:

T: 800.715.0944

E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
2. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
3. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
4. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
5. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
8. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. Tom Shaws NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen
11. Anthrax vaccine produces immunity with nanoparticles, not needles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)...  Blueprint Medicines (NASDAQ: BPMC ) today ... of 9,367,708 shares of common stock at a ... shares of common stock issued upon the full ... purchase additional shares. The gross proceeds from the ... $168.6 million, before underwriting discounts and estimated offering expenses. ...
(Date:5/5/2015)... May 05, 2015 VetStem Biopharma, ... Animal Health, Jeffrey Schaffer, DVM, as Director of ... 15 years of experience in the veterinary regenerative ... addition to our veterinarian lead organization”. Dr. ... “Dr. Schaffer will be responsible for all technical ...
(Date:5/5/2015)... May 5, 2015  Tikcro Technologies Ltd. (OTCQB: ... to continue trading on OTCQB  Marketplace, the market ... Marketplace allows for a continuous public market for ... have real-time quotes and market information on us ... OTCQB Marketplace includes U.S. and international companies in ...
(Date:5/5/2015)... 5, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... , President and Chief Executive Officer, will present ... DATE:  Thursday, May 7, 2015     TIME:  11:30 am ... > click the red "register/ watch presentations" button ... online event where investors are invited to ask ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2
... ... Technology for In Situ Monitoring and Control of Complex Particle and Droplet Systems, which ... situ and in real time. , ... (PRWEB) March 10, 2010 -- When is turbidity not enough? For ...
... ... , ... ... , ...
... ... ... ... ...
Cached Biology Technology:Beyond Turbidity: Selecting Appropriate Technology for in Situ Monitoring and Control of Complex Particle and Droplet Systems 2IGEN Networks engages new auditors and converts debt 2A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 2A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 3A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 4A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 5A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 6A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 7A Year Since Obama's Lifting of Ban on Stem Cell Funding, Boston Team Ready to Distribute Lines Worldwide But Obstacles Remain. New Website to End Public Confusion and Push Science Forward 8
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... used by a species of tropical seaweed to ward ... humans. The compounds are part of a unique chemical ... and that may provide a wealth of potential new ... at the Georgia Institute of Technology found that the ...
... note in the symphony of good news that usually ... promise in regenerative medicine, thanks to their ability to ... possible to markedly improve the effectiveness of many medical ... grafts for treating burn victims, and the treatment of ...
... of the parasitic worm that causes trichinosis, a disease ... wild game animals, such as bear and walrus. ... of Medicine in St. Louis and their collaborators report ... Trichinella spiralis , which provide potential targets for new ...
Cached Biology News:Antifungal compound found on tropical seaweed has promising antimalarial properties 2Antifungal compound found on tropical seaweed has promising antimalarial properties 3Antifungal compound found on tropical seaweed has promising antimalarial properties 4Reprogrammed stem cells hit a roadblock 2Trichinosis parasite gets DNA decoded 2
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
Normal sheep serum collected from healthy normal sheep...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Biology Products: